The INDIGO trial, a phase 3 study involving 331 patients with residual or recurrent grade 2 IDH-mutant gliomas, demonstrated the efficacy of vorasidenib, an oral, brain-penetrant inhibitor of mutant IDH1 and IDH2. This evidence concerns the gene IDH1 and glioma.